Sven Ante Lundberg
Board ChairDr. Sven Ante Lundberg, also known as Bill, M.D., is Board Chair of Yarrow Bioscience, Inc since July 27, 2026. Dr. Lundberg is Venture Advisor of Forge Life Science Partners. He served as Chief Executive Officer, President and Executive Director of Merus N.V. since December 31, 2019 until December 11, 2025 and was its Non-Executive Director from June 2019 to December 31, 2019 and served as its principal operating officer until January 04, 2023 and served as its Principal Financial Officer since December 31, 2019 until June 2023. Dr. Lundberg served on the board of directors of the publicly traded life science company Vor Biopharma until July 17, 2025. He serves as an Independent Director of Q32 Bio Inc. since December 2017. He served as Non-Executive Director at Merus N.V. from June 2019 to January 2020 and served as its Board Observer from March 2019 to June 2019. Dr. Lundberg was Head of Scientific Advisory Board at CRISPR Therapeutics AG since February 8, 2018. Dr. Lundberg has been Director of Alliance for Regenerative Medicine since 2018. Dr. Lundberg served as Chief Scientific Officer of CRISPR Therapeutics AG from January 2015 to February 8, 2018, where he was responsible for establishing and growing research and development in the United States and oversaw CRISPR’s first CRISPR-based product from inception to regulatory filing for clinical trials. From February 2011 to January 2015, Dr. Lundberg served as Head of Translational Medicine and Vice President at Alexion Pharmaceuticals, Inc. where he oversaw research and development from discovery through early-stage development. Dr. Lundberg has a wealth of knowledge and experience in the fields of immunology and oncology. Dr. Lundberg served as Director and Chief Medical Officer of Taligen Therapeutics, Inc. since April 2010, which was acquired by Alexion in 2011. Dr. Lundberg has held senior clinical and medical affairs roles in both large pharmaceutical and emerging biopharmaceutical companies, including Genzyme, Pfizer (formerly, Wyeth), Xanthus Pharmaceuticals and Antisoma Research Ltd. He received a BS with Biology from Massachusetts Institute of Technology. Dr. Lundberg received an M.D. from Stanford University and M.B.A. from the University of Massachusetts. He completed post-doctoral training at the Whitehead Institute/M.I.T. and clinical training in Medicine and Medical Oncology from Harvard and the Dana-Farber Cancer Institute.
Positions
- Company NameYarrow Bioscience, Inc.Stock CodeYARWPositionBoard Chair
